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ABSTRACT
Introduction: A number of studies suggest a
link between low levels of 25-hydroxy vitamin
D and incidence of acute and chronic pain.
Clinical studies of vitamin D supplementation
in patients with known vitamin D deficiency
have shown mixed results in improving pain
scores.
Methods: In this article, vitamin D deficiency
risk factors are observed and adequate levels of
25-hydroxy vitamin D defined. Clinical
supplementation with vitamin D is explored,
including the schedules used in published
clinical trials. Evidence of the effectiveness of
vitamin D supplementation for the treatment of
chronic pain conditions from double-blind
randomized controlled trials (RCTs) is
examined.
Results: The scientific evidence for vitamin D
as a treatment option for chronic pain is limited
due to lack of RCTs. It cannot be stated
conclusively that vitamin D deficiency is
directly linked to the etiology or maintenance
of chronic pain states.
Conclusion: There remains a growing body of
both clinical and laboratory evidence pointing
to a potential relationship between low levels of
25-hydroxy vitamin D and a variety of chronic
pain states. More focused research involving
large RCTs is necessary.
Keywords: Chronic Pain; Pain Processes;
Supplementation; Vitamin D deficiency
INTRODUCTION
It appears that circulating vitamin D, the parent
compound for tissue vitamin D activation, has
an important direct physiological role beyond
what was originally anticipated through the
local tissue autocrine system [1]. A number of
studies have suggested a link between low levels
of 25-hydroxy vitamin D [25(OH)D] and the
incidence of both acute and chronic pain [2–5].
Clinical studies of vitamin D supplementation
in patients with known vitamin D deficiency
have shown mixed results in improving pain
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scores [6]. Vitamin D is cheap and has relatively
few adverse effects. Its use in chronic pain could
therefore be advocated even if the benefit was of
modest size [4]. In general, there is a positive
public perception of vitamin supplementation
which could result in high rates of adherence
[4].
Synthesis, Absorption, and Metabolism
of Vitamin D
Chemically, vitamin D is a fat-soluble
secosteroid (that is, a steroid in which one of
the bonds in the steroid rings is broken). The
most common forms are vitamin D3
(cholecalciferol) and vitamin D2
(ergocalciferol), which are collectively known
as calciferol. Although it is called a vitamin,
vitamin D is really a hormone. It can be
produced endogenously by humans in the skin
from a precursor 7-dehydrocholesterol which is
converted to vitamin D3 after exposure to
ultraviolet B. Vitamin D can also be obtained
from a limited number of dietary sources;
vitamin D2 from plant origins and vitamin D3
from animal origins. However, few foods have
naturally occurring substantial vitamin D2 and
vitamin D3 levels to make this a significant
source of vitamin D in humans.
Vitamin D from the skin and diet is
hydroxylated in the liver by one of several
cytochrome P450 enzymes to the prehormone
25-hydroxy vitamin D [calcidiol, or 25(OH)D]
that is encoded by the gene CYP27A1 [7–9].
Most circulating 25(OH)D and the active form
of vitamin D, namely 1,25-dihydroxy-vitamin D
[1,25(OH)2D3], are transported in the blood
bound to vitamin D-binding protein (DBP;
80–90%) and to albumin (10–20%); only a
small fraction remains free or unbound [10].
However, vitamin D can also be
hydroxylated to 25(OH)D in all tissues of the
body, achieving autocrine production of
25(OH)D in these tissues [1]. 25(OH)D is then
further metabolized in the kidneys and possibly
in a wide variety of extra-renal tissues by the
enzyme 25-hydroxyvitamin D-1a-hydroxylase
(CYP27B1) to its active form, namely, 1,25-
dihydroxy-vitamin D [1,25(OH)2D3]. Vitamin D
exerts its effects by modulating gene expression
after binding to vitamin D receptor (VDR).
There appear to be potential genetic
polymorphisms in key genes with vitamin D
exposure that can influence bioavailability,
transport, and distribution in lipid storage
pools, metabolism, and action of vitamin D [8].
Chronic Pain
The International Association for the Study of
Pain (IASP) defines chronic pain as ‘‘pain that
has persisted beyond normal tissue healing
time’’. This is taken (in absence of other
criteria) to be 3 months [11]. However, some
chronic pain disorders are characterized by
recurrent short acute episodes and
exacerbations such as trigeminal neuralgia and
rheumatoid arthritis.
Chronic pain can be produced after tissue
damage (or inflammation), nerve damage, and
after alteration of normal neural function.
Chronic persistent pain leads to chemical,
functional, and anatomical changes
throughout the nervous system (in the
periphery, spinal cord, and brain) [12–14]. In
chronic pain states, the nervous system is altered
to produce spontaneous pain that arises without
any apparent peripheral stimulus as well as a
hypersensitivity to peripheral stimuli [15–18].
Pain hypersensitivity potentiates hyperalgesia
(the exaggerated and prolonged response to
noxious stimulation) and allodynia (pain
resulting from a stimulus that is normally non-
painful) [19]. Reduced descending inhibition in
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the central nervous system results in increased
peripheral noxious signals that provide messages
to the brain, and result in an increased
experience of pain [20].
THE INTERFACE OF VITAMIN D
AND CHRONIC PAIN
Research has shown that vitamin D exerts
anatomic, hormonal, neurological, and
immunological influences on pain
manifestation, thereby potentially playing a
role in the etiology and maintenance of
chronic pain states and associated
comorbidities [21–24]. 1,25(OH)2D3 (i.e.,
calcitriol) is an active vitamin D metabolite. It
plays a role in many biological processes,
especially in bone metabolism and muscle
function, and is mediated by VDRs [25].
Vitamin D supplementation has been found to
improve bone density and musculoskeletal
symptoms [26]. Vitamin D deficiency causes
muscle weakness and pain in children and
adults [27, 28]. Low bone density and
osteopenia appear to contribute to chronic
pain in patients with cystic fibrosis, and are
related to low 25(OH)D levels [29, 30].
Low 25(OH)D levels have been found to be
related to heightened central sensitivity
(particularly augmented pain processing) upon
mechanical stimulation in chronic pain patients
[31]. Migraine and fibromyalgia represent a
central neural hypersensitivity [32, 33].
Activated microglia, astrocytes, and spinal glia
release a variety of neuroexcitatory substances
(nitric oxide, excitatory amino acids,
proinflammatory cytokines, and mediators)
that potentially initiate and maintain the
neural hypersensitivity state seen in chronic
pain states [32]. As a neuroactive steroid,
vitamin D can modulate neuronal excitability
including spontaneous regular firing, action
potential duration, intrinsic excitability and
sensitivity to neurotransmitters (gonadotropin-
releasing hormone, opioidergic neurons) as well
as to neurotransmitter receptors such as gamma-
aminobutyric acid and N-methyl-D-aspartate
[34–36]. Vitamin D plays a fundamental role in
astrocyte detoxification pathways, and thereby
exerts a neuroprotective effect [37]. Vitamin D
suppresses tumor necrosis factor alpha (TNFa),
macrophage colony-stimulating factor (M-CSF),
and inducible nitric oxide synthase in astrocytes
and microglia [38]. TNFa has been convincingly
implicated at both peripheral and central levels
of sensitization [39]. M-CSF is a cytokine that
stimulates proliferation, differentiation, and
survival of monocytes and macrophages.
Macrophages can release many inflammatory
mediators, including proinflammatory
cytokines, particularly TNFa and interleukin-1
beta (IL-1b), nerve growth factor (NGF), nitric
oxide (NO), and the prostanoids [40]. By limiting
M-CSF, vitamin D has the potential to inhibit
pain pathways. The presence of VDR, 1a-
hydroxylase, and DBP in the hypothalamus is
suggested as themechanism by which vitamin D
deficiency is implicated in the pathophysiology
of various primary headache disorders [41].
Vitamin D upregulates the synthesis of
neurotrophins such as NGF, neurotrophin 3,
and glial cell line-derived neurotrophic factor,
whereas neurotrophin 4 is down-regulated [37,
38, 42–44]. Through this system, vitamin D can
potentially affect the development of neurons, as
well as their maintenance and survival. NGF is a
well-established inflammatory mediator and has
direct effects on the sensory nerve endings
causing hypersensitivity, amplification of
sensory input signals, and enhanced
innervation of injured tissue [40, 45–47].
Individuals with sickle cell disease may
develop chronic pain for a variety of reasons
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including vascular occlusive bone infarction,
peripheral nerve injury, central pain
sensitization, as well as hyperalgesia syndrome
from prolonged high-dose opioid use [48].
VITAMIN D DEFICIENCY
General Prevalence of and Risk Factors
Associated With Vitamin D Deficiency
There appears to be a worldwide trend towards
nutritional vitamin D deficiency that is causing
concern [9]. Estimates of vitamin D deficiency
vary across the world and within countries
themselves. It has been estimated that a wide
range (20–100%) of elderly men and women
living in the community in the United States,
Canada, and Europe are vitamin D deficient [49].
The major cause of vitamin D deficiency is
decreased sun exposure that limits the synthesis
of vitamin D [49]. This could occur through
stringent application of sunscreen, or active
avoidance of the sun for presumed health
reasons [50]. Women who cover themselves for
cultural or religious reasons are at risk of vitamin
D deficiency as well [51]. People with naturally
dark skin tone appear to require at least three to
five times longer sun exposure to make the same
amount of vitamin D as a person with a white
skin tone [49]. Peoplewithdark-colored skinwho
live far from the equator are at high risk of
developing a vitamin D deficiency. However,
there is also evidence that dark-skinned people
can be at risk even in sunny climate such as
Australia [50]. Age, gender, and race can be
factors associated with risk of vitamin D
deficiency. In the United States, serum levels of
25(OH)D (nmol/L) among 15,390 adult
participants more than or equal to 18 years of
age were evaluated [52]. White men and women
(83.0 and 76.0 nmol/L, respectively) had higher
mean serum levels of 25(OH)D than Hispanic
men and women (68.3 nmol/L and 56.7 nmol/L,
respectively; P\0.0001), and had higher mean
serum levels of 25(OH)D than black men and
women (52.2 and 45.3 nmol/L, respectively;
P\0.0001) as well. The prevalence of both mild
to moderate and severe deficiency of 25(OH)D
was higher among women (P\0.0001) and in
minority populations (P\0.0001). However,
even amongst white men, 34% were found to
have low 25(OH)D levels [52].
The elderly are particularly at risk as the
body’s ability to synthesize vitamin D in the
skin decreases with aging [21]. Being less mobile
and often confined indoors, their exposure to
sunlight can be limited. This applies particularly
to institutionalized individuals [50, 53]. Despite
the sunny climate in Australia, in a large sample
ofwomen in residential care in threeof the states,
mean 25(OH)D serum levels fell below 50, and
below 31.4 nmol/L if they were in high-level care
[54]. Neonatesmay be deficient due to low serum
maternal 25(OH)D levels caused by multiparity
and by dark maternal skin with restricted sun
exposure [50]. Exclusively breast-fed infants,
particularly if dark skinned with little exposure
to sunlight, are at risk as well [55].
Patients with malabsorption syndromes such
as cystic fibrosis, cholestatic liver disease,
chronic inflammatory bowel disease (Crohn’s
disease), or a short bowel syndrome are at risk of
developing vitamin D deficiency through
limited absorption of dietary vitamin D [50,
56]. Vegetarians may also be at risk of dietary
vitamin D deficiency [50]. Obesity is associated
with vitamin D deficiency in both adults and
children [57–60]. This could be related to
increased storage of vitamin D in adipose
tissue, limited sun exposure due to increased
clothing and immobility, or due to the fact that
low vitamin D levels cause parathyroid
hormone (PTH) excess and calcium influx into
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adipocytes, promoting weight gain [61].
However, it is not known whether adipose
tissue merely sequesters vitamin D and its
metabolites or whether it functions as a
storage pool from which vitamin D and its
metabolites can be mobilized [8].
People taking anticonvulsants, glucocorticoids,
rifampicin, or highly active antiretroviral drugs are
at higher risk of developing vitamin D
insufficiency [49, 50]. These drugs enhance the
catabolism of 25(OH)D and of 1,25(OH)2D3 [49,
50].
Defining Adequate of Vitamin D Levels
At present, assessment of serum 25(OH)D
provides the best measure of vitamin D repletion
in humans, reflecting exposure to dietary or
endogenous sources of vitamin D as well as
indicating other processes such as absorption
and metabolism [8, 10, 62]. One functional
definition of the optimal vitamin D status is the
25(OH)D levels thatmaximally suppress PTH [63,
64]; the reason for this is that the major stimulus
for PTH secretion is a low level of serum calcium
[7, 65]. It is generally agreed that the levels of PTH
will start to rise significantly once the serum
25(OH)D levels drops below 75 nmol/L [50].
Many vitamin D scientists advise that the
minimum serum 25(OH)D levels should be
75 nmol/L [9, 49, 66]. Most experts now define
frank vitamin D deficiency as a serum 25(OH)D
level of less than50 nmol/L [49, 50, 65, 67]. Serum
levels between 50 and 75 nmol/L are considered
to represent vitamin D insufficiency [9].
Clinical Supplementation with Vitamin D
Vitamin D supplementation increases 25(OH)D
serum levels and can therefore potentially
correct the effects of vitamin D deficiency [4].
The impact of dietary intake on vitamin D
metabolism and the reversibility of chronic pain
with normalization of serum 25(OH)D levels
remain unclear at present. Variation in vitamin
D dosing schedules could have a profound
effect in the outcome of clinical trials because
of the short circulating half-life of intact
vitamin D [1]. The cellular accessibility of the
parent compound vitamin D, as well as that of
25(OH)D, is important when considering
supplementing with vitamin D in a clinical
trial. 25(OH)D and vitamin D can be
internalized by cells through one of two
mechanisms. Free 25(OH)D can enter the cell
by diffusion across the cell membrane or by the
DBP receptor-mediated endocytosis by the
coreceptors megalin and cubilin [8]. Most
circulating vitamin D and 25(OH)D are
transported in the blood bound to DBP. The
25(OH)D is tightly bound to DPB. The amount
of DBP and its effect on free versus bound
25(OH)D could inversely affect the free
25(OH)D available for uptake by diffusion into
cells [8]. This simple diffusion is primarily
controlled by the dissociation constant of the
vitamin D compound to the DBP. The amount
of DBP could also directly influence the uptake
of 25(OH)D via the megalin and cubilin
coreceptor system [1].
Selection of dosing regimen, such as whether
to give supplements at daily, weekly, monthly,
or longer intervals, is important in clinical trials
of vitamin D as different regimes could
influence the outcomes of such studies. Long-
term daily dosing of vitamin D will result in a
slow rise in circulating serum 25(OH)D levels
that will reach a steady state at 3–6 months [1].
Stable circulating serum levels of both vitamin
D and 25(OH)D result from daily dosing
schedules, whereas weekly doses result in
varying serum levels of circulating vitamin D
but stable serum levels of 25(OH)D [68–70].
Acute or large bolus dosing with vitamin D
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appears to produce a variety of rates of 25(OH)D
[1].
A wide variety of schedules have been used
in published clinical trials (Table 1 [71–78] ).
However, clinical research studies have shown
that supplementary doses less than 1000 IU per
day of vitamin D results in only modest
increases in serum levels of 25(OH)D that may
be inconsequential for achieving optimal serum
levels of 75 nmol/L [79, 80].
There does not appear to be any variation in
tolerance or toxicity of vitamin D in terms of
the dosing regimen [1]. It has been suggested
that optimal benefits from vitamin D
supplementation would be achieved through a
daily dose of vitamin D to ensure stable
circulating serum levels over time [1]. Once-
daily dosing appeared to be more effective than
monthly or 3-monthly dosing in prevention of
respiratory tract infections [81]. However, poor
adherence with daily dosing of medications and
supplements is widely appreciated [72]. Thus,
higher and longer interval dosing is likely to
result in better adherence. Weekly dosing would
be preferable over monthly due to the 3–4 week
half-life of 25(OH)D [72]. In a recent study of
patients supplemented with either 1200 IU
daily or 50,000 IU weekly of vitamin D for
3 months, the serum 25(OH)D level improved
in both groups by almost 40%, but the
difference in improvement was not statistically
significant between the subgroups [82]. Four-
monthly vitamin D supplementation has also
been shown to result in positive functional
outcomes [78].
Studies have shown that time to equilibrium
for vitamin D supplementation is generally 3 to
6 months [83–87].
Vitamin D has relatively few (and usually
mild) adverse effects. Excessive inputs of
vitamin D potentially produce hypercalcemia,
renal stones, and renal calcification, with
kidney failure and death. Extremely high
serum levels of either 25(OH)D or of vitamin
D can result in hypercalcemia via two
mechanisms. Firstly, by directly causing high
intestinal calcium absorption and bone
resorption that is in excess of the kidney’s
ability to handle the calcemic load. Secondly,
by causing displacement of the active form of
the vitamin from circulating DBP by high levels
of 25(OH)D, resulting in an elevation of free
1,25(OH)2D3 [88]. It appears that the daily
intake of vitamin D necessary to achieve
serum levels of 75–110 nmol/L is not
associated with these risks. Excessive vitamin
D intake (over 50,000 IU per day) is rarely
associated with hypercalcemia [21]. Doses of
10,000 IU of vitamin D3 per day for up to




CONTROLLED TRIALS OF VITAMIN
D SUPPLEMENTATION IN PATIENTS
WITH CHRONIC PAIN
There are limited randomized double-blind
placebo-controlled trials of vitamin D
supplementation to determine the efficacy of
Table 1 Dosing schedules of vitamin D [68, 71–78]






a Four-monthly dosing schedule was only mentioned in
one research trial
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vitamin D treatment in chronic pain
conditions.
The authors searched MEDLINE (PubMed)
using the search terms ‘‘vitamin D and pain’’.
Limits in PubMed were set to ‘‘Randomized
Controlled Trials’’ (RCTs) and ‘‘humans’’. Full
publications in any language were included.
The search was conducted on March 11, 2015.
Two authors (E. E. S. and E. A. S.) independently
reviewed all titles and abstracts identified by the
search. Articles were selected for full-text review
if inclusion criteria were met, or if either
reviewer considered them potentially relevant.
Clinical studies were included only if they
reported on populations with chronic pain
conditions and investigated pain outcomes
after vitamin D supplementation. Data were
collected regarding study design, chronic pain
condition, population group, patient
characteristics, mean or median 25(OH)D
levels, treatment protocol (including types and
doses of vitamin D preparations administered),
concurrent other therapy, study duration, aim
of the study, and pain outcomes. To be
inclusive, chronic pain was defined in the
broadest possible terms. An improvement of
chronic pain with vitamin D treatment was
defined as a statistically significant
improvement compared to placebo. Pooled
analysis was not undertaken due to the
paucity and the heterogeneity of data. This
article is based on previously conducted studies
and does not involve any new studies of human
or animal subjects performed by any of the
authors.
The search identified 86 entries. Studies were
included if they were double-blind RCTs of
vitamin D supplementation compared to
placebo in the treatment of chronic pain
conditions.
Eight RCTs met these inclusion criteria.
Seventy-eight studies were excluded based on
the following criteria, namely: pain not
measured as an outcome (n = 25); acute pain
instead of chronic pain (n = 4); study was singly
blinded or not specifically described as double
blinded (n = 6); study design only (n = 1); not
all participants had chronic pain (n = 1); there
was no supplementation with vitamin D
(n = 4); and the study did not control for
vitamin D independent of other treatments
(n = 37). Only one reason for exclusion was
stated. However, some studies may have had
more than one reason for exclusion (see Table
S1 in the electronic supplementary material for
details). The 8 data sets ranged in size from 24 to
146 participants. The total number of
participants in the ‘‘pain’’ and ‘‘control’’ groups
was 620 of which 396 were female. The majority
of the studies were of high methodological
quality (Oxford Quality Score 5/5) suggesting
little likelihood of methodological bias [90].
There were five studies related to
musculoskeletal pain [91–95], of which two
were of diffuse or generalized musculoskeletal
pain [91, 92]. There were three studies of
specific musculoskeletal pain, two involving
osteoarthritis of the knees and one of
aromatase inhibitor-induced musculoskeletal
pain [93–95]. There was one study of each of
the following: polymyalgia rheumatica [96];
fibromyalgia [97]; and generalized pain of the
elderly [98]. Two studies [96, 98] had lower
Oxford Quality Scores and were potentially
prone to bias.
There were 5 studies, involving 400
participants, which showed a positive
correlation between vitamin D
supplementation and subjective pain rating.
The four other studies (220 participants)
showed no change in pain levels after
supplementation. The supplementation regime
varied widely and the vitamin D treatments
involved monthly equivalent doses that varied
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from 35,000 to 300,000 IU. Duration of
supplementation was from 1 to 24 months.
The results of this search are shown in
Table 2 [91–98].
DISCUSSION
Evaluation of clinical studies regarding the use
of vitamin D for the treatment of chronic pain
was previously undertaken in 2008 [6]. The
authors searched MEDLINE (PubMed) using
various search terms for vitamin D and pain
prior to September 2008. Twenty-two relevant
studies were identified that reported mean
25(OH)D levels and/or investigated the results
of vitamin D treatment in patients with chronic
pain conditions. Only five of these studies were
randomized double-blind trials of vitamin D
treatment. Vitamin D treatments involved
monthly equivalent doses between 1200 and
400,000 IU. Fourteen studies were in
musculoskeletal pain, five in chronic
widespread pain or fibromyalgia, one in
diabetic subjects with neuropathic pain, one
addressing an unusual hyperaesthetic pain
syndrome, and one in various conditions.
Duration of treatment was from a few days to
12 months, although most studies lasted
2 months or more. Treatment studies involved
733 patients. Randomized double-blind trials
involved 229 patients, of whom only 22 (10%)
were in a trial with a significant improvement in
pain with vitamin D, and then only on a pain
mobility measure; 207 patients were involved in
trials with no significant improvement in pain
with vitamin D. There was also no apparent
correlation between significant improvement in
pain with vitamin D and with a particular
preparation, dose, or condition. There was no
persuasive evidence of lower levels of 25(OH)D
in those with chronic pain than in the control
populations. There was a striking contrast in
treatment effects between randomized, double-
blind trials that minimized bias and those with
designs known to be subject to bias. In the
former, only 10% of patients were in trials
showing a benefit of vitamin D treatment; in
the latter, 93% were in trials showing a benefit
of vitamin D treatment [6]. This study
highlighted the need for further randomized
double-blind placebo-controlled trials.
A Cochrane review of randomized double-
blind trials of vitamin D supplementation
compared with placebo was published in 2010
[4]. The aim was to determine the efficacy of
vitamin D in the treatment of chronic pain
conditions. Only four studies (with a total of
294 participants) were included; eleven trials
were excluded due to poor methodological
design, or because not all participants received
a clearly defined chronic pain diagnosis [4]. The
studies included were similar in quality, used
analogous chronic pain conditions with
comparable outcome measures [91, 96, 99,
100]. Patients were supplemented with varying
amounts and formulations of vitamin D for
periods ranging from 16 weeks to 12 months. In
summary, out of the four trials reviewed, the
benefit of using vitamin D in chronic pain
treatment was only shown in one trial. In the
other three trials, there was no significant
beneficial effect of vitamin D over placebo.
Adverse effects of treatment were infrequent,
and occurred at the same rates in vitamin D and
placebo groups [96, 100].
Our study concurs with the results of the
previous review on the subject published in
2009 and the Cochrane review published in
2010, in that there is insufficient high-quality
evidence for a definitive effect of vitamin D in
chronic pain. However, a trend appears in a
positive direction indicating a beneficial effect
of vitamin D over placebo in chronic pain.
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The number of randomized placebo-
controlled double-blind studies is increasing
which is encouraging. Six of the RCTs
included in our study were published since
2011. Although the search strategy of this
comprehensive review was thorough, it is
possible that some randomized clinical trials
might not have been located. A positive
publication bias cannot be excluded as
journals are reluctant to publish negative
results. The overall picture generated by a
review of this type could thus be a false positive.
CONCLUSION
Studies using visual analog scale (VAS) pain
scores as the primary or solitary outcome
measure have shown mixed results in chronic
pain patients when evaluating the impact of
vitamin D supplementation in this condition
[82, 91, 101–103]. Significant improvements in
assessment of sleep, mood, pain levels, well-
being, and various aspects of quality of life
with vitamin D supplementation have been
shown [82, 104–107]. Whilst there is a growing
body of both clinical and laboratory evidence
pointing to a potential relationship between
low levels of 25(OH)D and chronic pain, it is
not possible to state conclusively that vitamin
D deficiency is directly linked to the etiology
or maintenance of chronic pain states. The
scientific evidence for the use of vitamin D as a
treatment option for chronic pain is limited at
present due to low-quality designs, and due to
the lack of RCTs.
A number of questions remain with regard to
supplementation of vitamin D in patients with
chronic pain. Vitamin D metabolism and action
needs to be further elucidated including extra-
renal activation and catabolism, distribution
and mobilization from body pools, and its
interaction with relevant genetic
polymorphisms [8]. There remains some
debate over the precise definition of vitamin D
deficiency or insufficiency based on the serum
levels of 25(OH)D. The influence of age and
body weight on the variability of the response
of serum levels of 25(OH)D to intake needs to be
clarified [8]. More focused research is necessary
involving larger double-blind RCTs. These need
to be stratified by baseline 25(OH)D levels, type
of pain, and the use of adequate doses of
vitamin D based on serum levels. More
research is necessary to determine whether or
not the effect of vitamin D supplementation is
limited to patients who are vitamin D deficient.
The optimal dose and length of time needed for
supplementation need to be assessed as well.
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